多替阿巴拉米片上市了没？

AIDS is an extremely harmful infectious disease. Currently, there is still a lack of drugs to cure HIV in the world. AIDS patients suffer from the torture of the disease and the strange eyes of others. Current effective therapeutic drugs mainly reduce viral load, reconstruct and maintain immune function, and reduce morbidity and mortality. It is a new three-in-one compound drug for the treatment of AIDS. So, when will Suimeikai (Doteta Abalamid Tablets) be launched?

On July 26, the State Food and Drug Administration (CFDA) approved the new AIDS treatment compound preparation Suimeikai (chemical name: Dolutea Paramid Tablets) to enter China. As an innovative single-pill compound preparation with obvious clinical therapeutic advantages, Suimeikai can provide great convenience for the treatment of AIDS patients and has received priority review and approval from the State Food and Drug Administration. The anti-AIDS single-tablet compound drug doptabalamid tablets has been approved for marketing by the State Food and Drug Administration, bringing new medication options to Chinese AIDS patients.

my country began to implement the "Four Frees and One Care" policy in 2003. In 2006, the policy was institutionalized and legalized through the "Regulations on the Prevention and Treatment of AIDS", which greatly reduced the economic burden of AIDS patients and played an important role in effectively controlling the AIDS epidemic, which has been praised internationally.

There are currently three key research and development directions for anti-AIDS drugs: first, further optimizing dosage forms, including the development of compound preparations and long-acting drugs. Second, to achieve functional cure for AIDS patients, that is, after the patient stops taking the drug, the HIV virus cannot be detected in the blood, and the corresponding side effects will be reduced after the patient stops taking the drug, greatly improving the patient's quality of life. Zhang Tong emphasized that the earlier the treatment, the greater the possibility of achieving functional cure. Third, the research and development of AIDS vaccines, including preventive and therapeutic vaccines, are currently in the research stage, and no mature vaccine has yet been released.

(Dolutea Paramid Tablets) has recently been launched in China. Dolutegra Abalamid Tablets have the characteristics of good tolerability, high resistance barrier and few drug interactions. One tablet is taken once a day, which can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life. AIDS is gradually becoming a preventable, controllable and manageable chronic disease like hypertension and diabetes.